Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab maintenance after induction chemoimmunotherapy for primary central nervous system lymphoma
ACTRN12619000518167Phase 2Active, not recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, open-label trial of pembrolizumab in primary central nervous system lymphoma (PCNSL) and diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoints: Progression-free survival at 1 year and Adverse events, serious adverse events, and events of clinical interest. Started Apr 2022; status: active, not recruiting.
02
Drugs
03
Conditions
primary central nervous system lymphoma (PCNSL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ACTRN12619000518167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000518167.